Floatz logo

AEX4089DC1

Non-small Cell Carcinoma

MacroGenicsantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Non-small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Tsc-204-A0101
TScan Therapeutics, Inc.
Phase 1CC
Tsc-203-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-201-B0702
TScan Therapeutics, Inc.
Phase 1CC
Tsc-204-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-202-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-200-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-204-C0702
TScan Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

AEX4089DC1 is also rated in:

Androgen-Independent Prostatic CancerDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Anal NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →